Webinar
on demand
17
Oct
2022
18
00
CEST
Diagnosis of drug induced Interstitial Lung Disease (ILD) in cancer patients: tips for practice

This session is part of the SPCC Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project. Following the Task Force - held in 2022 - the fourth phase of the project will focus on the results emerged from the discussion on the new strategies to tackle adverse events on Interstitial Lung Disease Cancer.

 

Speakers
Discussant
Addeo Alfredo

Oncology Division, University Hospital Geneva, Geneve, Switzerland
Discussant
Rugo Hope

Winterhof Family Professor of Breast Cancer Director, Breast Oncology and Clinical Trials Education Medical Director, Cancer Infusion Services, San Francisco, USA
Expert
Bendstrup Elisabeth

Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
Expert
Schaefer-Prokop Cornelia

Radiologist at Meander Medical Centre, Amersfoort, The Netherlands
This material is part of Educational Project:
2022 - Adverse Events Management and Interstitial Lung Disease (ILD) Detection Project